P1077BF: Breastfeeding Version of the PROMISE Study (Promoting Maternal and Infant Survival Everywhere)

This trial was terminated November 6, 2019.

This multi-country trial is being conducted in India, Malawi, South Africa, Tanzania, Uganda, Zambia, and Zimbabwe, conducted under the International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Network and funded by the U.S. National Institutes of Health..

1077BF is a randomized strategy trial, which is part of the PROMISE studies (1077BF, 1077FF, P1084s, and 1077HS). The Promoting Maternal and Infant Survival Everywhere (PROMISE) Protocol is a research protocol of the IMPAACT network designed to address in an integrated and comprehensive fashion three critical questions currently facing HIV-infected pregnant and postpartum women and their infants:

• 
  What is the optimal intervention for the prevention of antepartum and intrapartum transmission of HIV?
• 
  What is the optimal intervention for the prevention of postpartum transmission in breastfeeding (BF) infants?
• 
  What is the optimal intervention for the preservation of maternal health after the risk period for prevention of mother-to-child-transmission ends (either at delivery or cessation of BF)?

This version of the PROMISE protocol (IMPAACT 1077BF) is intended for those sites where the standard method of infant feeding is breastfeeding.